Explore life science & biotech companies in Oxford, home to one of the world's leading biotechnology and life science clusters.
AI platform integrating biology, chemistry and automation for drug discovery
Recursion is a clinical-stage biotechnology company using AI and robotic wet-lab automation to industrialise small molecule drug discovery. Its platform integrates phenomics, transcriptomics, proteomics and patient data to identify and optimise drug candidates at scale. Following its acquisition of Oxford-based…
AI-driven combinatorial analytics platform for chronic disease biology
PrecisionLife is a computational biology company applying AI-driven combinatorial analytics to complex chronic diseases. Its platform identifies causal biological mechanisms and patient subgroups at a resolution not achievable by conventional genomic methods, enabling novel drug target discovery, patient…
Native mass spectrometry platform for small molecule drug discovery
OMass Therapeutics is a biotechnology company developing small molecule therapeutics against membrane proteins, GPCRs, and intracellular complexes that have historically been difficult to drug. Its proprietary platform combines native mass spectrometry, novel biochemistry, and custom chemistry to interrogate protein…
Clinical-stage oncology biopharma developing the bispecific antibody ivonescimab
Summit Therapeutics is a clinical-stage oncology company with UK research operations originating from VASTox, a University of Oxford spin-out. The company's lead candidate, ivonescimab, is a bispecific antibody targeting PD-1 and VEGF, in-licensed from Akeso and now in multiple global Phase III trials across non-small…
Academic protein informatics and antibody modelling tools
Oxford Protein Informatics Group is a University of Oxford research team led by Professor Charlotte Deane, developing computational methods for protein structures and interactions. Its researchers apply machine learning and bioinformatics to antibody modelling, immunoinformatics, protein engineering and drug…
Bioinformatics, software and compliance consultancy for biotech companies
Prismea is a provider of bioinformatics, software and cloud consultancy services for biotechnology companies. The company supports biotech clients with data analysis across genomics, imaging, spectroscopy, epidemiology and metabolomics, alongside custom software development, cloud infrastructure management and…
PET radiopharmaceutical diagnostics for cancer imaging
Blue Earth Diagnostics Limited is a molecular imaging company developing and commercialising PET radiopharmaceuticals for cancer diagnosis and treatment planning. The company serves clinicians, healthcare systems and patients by providing administered imaging agents that support clinical decision making in oncology.…
Biotech venture builder co-creating and scaling drug discovery companies
Molecule to Medicine (MTM) is a biotech venture builder that co-creates, builds, and scales drug discovery companies within a shared operational ecosystem, combining drug discovery expertise with shared infrastructure to enable rapid company formation. UK operations are based at Milton Park, Abingdon, with a further…
Antimicrobial and biocompatible surface coatings for orthopaedic implants
Accentus Medical is a surface engineering company developing and applying biocompatible and antimicrobial coatings for implantable medical devices, particularly orthopaedic implants. Its technologies include plasma-sprayed titanium and hydroxyapatite coatings that support bone integration, and silver-ion surface…
Contactless respiratory monitoring and digital biomarkers for clinical trials
Albus Health is a clinical research technology company developing passive, contactless monitoring for respiratory studies and pharmaceutical trials. Its bedside Albus Home system combines acoustic and other sensors to measure nocturnal cough, breathing and environmental conditions without requiring patients to wear…
CSF-1R antibody therapy for tenosynovial giant cell tumour
SynOx Therapeutics is a late-stage biopharmaceutical company developing emactuzumab, a humanised monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumour and other macrophage-driven conditions. Emactuzumab was licensed from Roche and inhibits the CSF-1 receptor to deplete…
Cancer immunotherapies targeting novel antigens from the dark genome
Enara Bio is a clinical-stage biopharmaceutical company developing cancer immunotherapies directed against Dark Antigens, a class of cancer-specific targets derived from previously uncharted genomic dark matter. Its platform integrates bioinformatics, immunopeptidomics, and immunology to discover and validate novel…
Specialist CRO for drug and agrochemical metabolite synthesis and characterisation
Hypha Discovery is a specialist contract research organisation supporting pharmaceutical and agrochemical companies worldwide. The company produces and purifies drug and agrochemical metabolites using microbial biotransformation, recombinant enzyme systems and late-stage chemical synthesis, supporting metabolite…
Science and innovation campus in Oxford's Cowley district
ARC Oxford is an 88-acre science and innovation campus located in Cowley, Oxford, operating as part of the Advanced Research Clusters network owned by Brookfield. Formerly Oxford Business Park, it was relaunched under the ARC brand in September 2022. The campus hosts over 35 organisations including a growing number of…
Small molecule GPR65 inhibitors restoring immune response in solid tumours
Pathios Therapeutics is a clinical-stage drug discovery company developing small molecule inhibitors of GPR65, a pH-sensing G protein-coupled receptor that drives immunosuppressive polarisation of tumour-associated macrophages in the acidic tumour microenvironment. By blocking GPR65, Pathios aims to restore…
Precision oncology drugs and vaccines for cold tumours
IngenOx Therapeutics Limited is a clinical-stage biopharmaceutical company developing precision oncology drugs and cancer vaccines for difficult-to-treat tumours. The company serves oncology patients and clinical development partners through a pipeline spanning small molecule immunomodulators, PRMT5 inhibition and…
Non-viral gene therapy platform enabling durable nuclear DNA delivery
Gramics Bio develops a gene therapy platform solving a key limitation of lipid nanoparticle delivery: enabling therapeutic DNA to reach the cell nucleus for durable expression without viral vectors. By programming specificity into synthetic DNA sequences rather than new delivery chemistries, the technology combines…
ADC pipeline targeting mutant stem cells in blood cancers
Alethio Therapeutics Limited is a preclinical-stage biotechnology company developing antibody-drug conjugates for myeloproliferative neoplasms, a group of chronic blood cancers. Its pipeline targets the mutant stem and progenitor cells that drive disease progression and fibrosis, with the aim of modifying rather than…
T cell immunotherapies for infectious disease, cancer and autoimmunity
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific T cell immunotherapies for chronic infectious diseases, autoimmune conditions, and cancer. Its pipeline is built on four proprietary viral vector and synthetic immunotherapy platforms and includes clinical candidates…
Off-the-shelf cancer immunotherapies targeting solid tumours
Scancell is a clinical-stage biotech developing active immunotherapies and antibody-based therapeutics for cancer. Its pipeline spans DNA cancer vaccines, peptide immunotherapies and tumour-specific monoclonal antibodies targeting glycans expressed on cancer cells. Lead programmes iSCIB1+ and Modi-1 are in Phase 2…